 RedHill Biopharma Ltd NASDAQ:RDHL has said that because its opaganib treatments proposed mechanism of action is not impacted by spike protein mutations, the drug is expected to be unaffected by mutations associated with the Omicron and other known coronavirus COVID-19 variants of concern. The company noted that increased hospitalizations in South Africa due to Omicron highlight the urgent need for drugs aimed at moderately severe COVID-19 patients with pneumonia requiring hospital treatment. 